2. Signaling Pathways
  3. Cytoskeleton
  4. Claudin
  5. CLDN18 Isoform
  6. CLDN18 Inhibitor

CLDN18 Inhibitor

CLDN18 Inhibitors (4):

Cat. No. Product Name Effect Purity
  • HY-P991564
    Arcotatug
    		Inhibitor 98%
    Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs.
  • HY-P991681
    Emaretamig
    		Inhibitor
    Emaretamig is a humanized IgG1κ monoclonal antibody inhibitor targeting CLDN18 and CD3E. Abdakibart can be used for cancers like gastric and pancreatic cancer research.
  • HY-P991163
    Tixentamig
    		Inhibitor ≥99.0%
    Tixentamig is a bispecific monoclonal antibody targeting human CD3 ε and CLDN18 (claudin 18). Tixentamig is promising for research of cancers.
  • HY-P992412
    MIL93
    		Inhibitor
    MIL93 is a humanized defucosylated IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001).